Home Featured Page 240

Featured

Latest

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Scientists Isolate Two New Compounds from Toad Venom

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in...

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to...

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...

Microdosing LSD Makes Me a Better Mom

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling...

EDITOR PICKS

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.